港股異動丨藥明生物跌超8%創7年新低,上半年淨利下滑33.9%,不派息
藥明生物(2269.HK)盤中跌超8%至10.42港元,股價創2017年8月以來新低,市值跌至432.7億港元;
該股曾於2021年7月創出148港元的歷史最高價。公司昨晚公佈業績顯示,2024年上半年實現收益85.74億元,同比增長1%;公司擁有人應占純利14.99億元,同比減少33.9%;經調整純利跌21%至22.5億元。每股基本盈利為0.37元,同比減少32.7%。董事會決定不派發中期股息。藥明生物上半年毛利率由41.9%跌2.8個百分點至39.1%,因來自發現服務減少的影 響,以及新冠項目取消,上半年中國的工廠利用率略低於去年同期。藥明來自北美的收入增28%至50.1億元,但來自中國及歐洲的收入分別下跌21%及27%,至14.2億及18.6億元。藥明指出,生物藥開發過程階段正在進行的綜合項目達742個,其中359個為臨牀前開發,早期(第I及II期)臨牀開發311個,後期(第III期)臨牀開發56個,商業化生產16個。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.